ライフサイエンスコーパス: RAEB-t

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 asts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2).

2 f relapse was 40% for secondary AML, 40% for RAEB-T, 26% for RAEB, and 0% for RA or RARS (P =.0009).

3 JMML, 31% +/- 26%; RA and RAEB, 29% +/- 16%; RAEB-T, 30% +/- 18%; antecedent MDS, 50% +/- 25%; and de

4 fractory anemia with excess blasts [RAEB] or RAEB-t, 62 patients) to receive fludarabine + ara-C + id

5 es for patients with RAEB in transformation (RAEB-T) (69%) or antecedent MDS (81%) were similar to de

6 Among 18 patients with RAEB-T/AML or CMML, 6 had relapse (CI at 3 years, 28%),

7 ransformation or acute myelogenous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (

8 RAEB, essentially identical to the rates in RAEB-t and AML, but event-free survival (EFS) from CR an

9 anemia with excess blasts in transformation (RAEB-t), and especially patients with RAEB, receive chem

10 anemia with excess blasts in transformation (RAEB-T), and RAEB-T/secondary MDS.

11 blast percentage (5% to 19% RAEB, 20% to 29% RAEB-t, and > or = 30% AML).

12 yelocytic leukemia [APL] excluded), 106 with RAEB-t, and 52 with RAEB.

13 anemia with excess blasts in transformation [RAEB-T] and tAML [MDS transformed into AML]), colony num

14 in RAEB than in AML or RAEB-t, with AML and RAEB-t being identical.

15 tics, a diagnosis of RAEB rather than AML or RAEB-t had no effect on EFS from start of Rx, EFS from C

16 anemia with excess blasts in transformation (RAEB-T) had apoptosis levels in lymphocytes similar to t

17 ition, transplantation before progression to RAEB-T, if possible, may reduce the risk of relapse.

18 anemia with excess blasts in transformation (RAEB-t), or RAEB.

19 anemia with excess blasts in transformation (RAEB-t), or refractory anemia with excess blasts (RAEB).

20 this analysis was to see if diagnosis (RAEB, RAEB-t, or AML) affected outcome.

21 anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on loc

22 (CFU)-leukemia formation in 9 of 15 CMML and RAEB-t patient specimens, whereas VEGF stimulated leukem

23 The poor prognosis of many RAEB or RAEB-t patients, if untreated, led us to give them AML R

24 cs, age, etc, but not a diagnosis of RAEB or RAEB-t per se.

25 As previously found, a diagnosis of RAEB or RAEB-t rather than AML was insignificant.

26 xcess blasts in transformation (RAEB-T), and RAEB-T/secondary MDS.

27 analyses suggested a trend for patients with RAEB-t to have better EFS from start of Rx than patients

28 P = .04) and on disease morphology (66% for RAEB-T v 38% for RAEB and CMML, P = .05).

29 However, patients with RAEB or RAEB-t were more likely to have poor prognostic characte

30 dministering AML Rx to patients with RAEB or RAEB-t who have poor prognosis without treatment is iden

31 survival, were poorer in RAEB than in AML or RAEB-t, with AML and RAEB-t being identical.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。